Immune modulation treatments-where is the evidence?

Area of Science:

• Reproductive Immunology
• Assisted Reproductive Technology

Background:

• Recurrent embryo implantation failure is a significant challenge in assisted reproductive technology (ART).
• The maternal immune system's role in early pregnancy and placentation is increasingly recognized.
• Peri-implantation immunomodulation is considered a potential therapeutic strategy.

Purpose of the Study:

• To critically evaluate the clinical evidence supporting immunomodulation for implantation failure.
• To assess the current utility and limitations of immunosuppressive treatments in IVF.
• To explore future directions for treating implantation failure.

Main Methods:

• Review of existing literature on immunomodulation in IVF and pregnancy.
• Analysis of the clinical evidence base for immunosuppressive therapies.
• Discussion of diagnostic challenges and potential for phenotyping.

Main Results:

• The clinical evidence supporting immunosuppressive treatments for implantation failure is currently weak and difficult to apply practically.
• Justifications for current practices often rely on patient expectations and commercial factors rather than robust data.
• Existing literature, despite limitations, suggests potential avenues for future research.

Conclusions:

• The current evidence base does not support the routine clinical use of immunomodulation therapies in patients undergoing in vitro fertilization (IVF).
• Recurrent implantation failure requires thorough phenotyping and etiological investigation, moving beyond symptom management.
• Future research should focus on precise patient phenotyping to identify specific subgroups who may benefit from targeted immunomodulatory interventions.